The year 2008 will see the continued expansion of Current Oncology, Canada’s only
multidisciplinary journal devoted to cancer. In that spirit, the supplement “Going
Beyond Efficacy,” edited by Dr. Sunil Verma, is being published together with this
first issue of main journal. Dr. Verma asked leaders from across the country to focus
on some serious issues being faced by cancer patients and their health care providers.
The result is an eclectic mix of topics, including management of nausea and vomiting,
neutropenia and anemia, thromboembolism, and iatrogenic osteopenia; use of bisphosphonates
and concerns regarding bisphosphonate-related osteonecrosis; and approaches to bone
metastasis and palliation. The supplement is not “bagged” with the current issue,
but will be published simultaneously online at the Current Oncology Web site (www.current-oncology.com).
I am also very pleased to add that Dr. Verma has accepted an invitation the join the
editorial board of the journal, co-editing the Medical Oncology section, and that
Dr. Raymond Nagle has also agreed to join us and to edit a new section on Oncologic
Pathology. Also joining us, I am very pleased to report, are Drs. Torgny Stigbrand
(Biomarkers in Oncology) from Umeå, Sweden, Herbert Nieburgs (Oncologic History) from
Worcester, Massachusetts, and Victor Ling (Translational Research) from Vancouver,
British Columbia.
In the issue now in your hands, I am delighted to include an Updates and Developments
in Oncology guest editorial by Drs. Serge Hardy and Michel Tremblay, discussing the
“changing” role of protein tyrosine phosphatases. In addition, I note that Dr. Tremblay
has graciously accepted an invitation to become involved on our editorial board, which
has continued to increase in breadth and calibre throughout 2007.
Drs. Stephen Sagar and Raimond Wong have written the first of a two-part series on
Chinese medicine and biomodulation in cancer patients, the second part of which is
scheduled for the second issue of 2008. Our guidelines series includes recommendations
on supportive care of neutropenia by Dr. Tom Kouroukis and colleagues (a topic therefore
deliberately not covered in “Going Beyond Efficacy”) and cardiac management during
adjuvant trastuzumab therapy from the Canadian Trastuzumab Working Group. Case report
topics include radiation recall dermatitis and (illegal) drug-induced “crack lung
and heart.” Dr. Nancy Levesque and colleagues discuss the use of high-dose interferon
alfa-2b in melanoma, and writer Maya Chaddah reports on the effective—and expanding—role
of the Ontario Cancer Research Ethics Board.
In regard to future articles, I urge all authors considering online submission to
carefully review the changing requirements for such submissions. Modifications have
been made to reflect the needs of our indexing agencies and the recent policy changes
concerning conflict of interest, informed consent, and human and animal rights published
last year by the International Committee of Medical Journal Editors.
The stated aim of Current Oncology is that it remain complimentary for our readership,
a goal that will likely continue for the foreseeable future. The costs of publication
are, in large part, borne by advertising revenues and unrestricted educational grants,
mainly from the pharmaceutical industry. I have never felt that this practice has
caused a conflict of interest, given the high calibre of our editorial writers and
the total acceptance of this position by our colleagues in industry. In the present
issue, we are embarking on a new concept with the appearance of specific information
updates again sponsored by unrestricted grants and written by experts in their respective
fields, at the editorial board’s specific invitation. We see these “updates” as a
fast track to publication, but one nonetheless subject to independent peer review.
Our thanks to Drs. Sunil Verma and Anil Joy for stepping up and testing out this concept
for us.
Lastly, a happy and productive 2008 to all of you from all of us at Current Oncology,
Canada’s multi-disciplinary cancer journal, as we enter our 15th year of publication
and approach our 300th published manuscript.